Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela K Green

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
JAMA Network Open|January 19, 2021
Challenges in Assessing the Cost-effectiveness of Cancer ImmunotherapyAngela K Green
Gynecologic Oncology|July 27, 2021
Novel therapy in endometrial cancer: How much will we pay?Angela K Green, Vicky Makker
Annals of Internal Medicine|January 4, 2018
Model-Based Eligibility for Lung Cancer Screening: Where Theory Meets PracticeAngela K Green, Peter Bach
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2018
Can We Afford That CAR? Confronting the Effect of Novel Immunotherapies on Future Health Care CostsAngela K Green, Leonard B Saltz
Cancer|December 10, 2015
Genomic profiling of advanced bladder cancer to guide the use of targeted therapeuticsAngela K Green, Matthew I Milowsky
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|March 28, 2020
A Review of Immune Checkpoint Blockade Therapy in Endometrial CancerAngela K Green, Jacqueline Feinberg, Vicky Makker
The Lancet. Oncology|February 13, 2019
Female representation among US National Comprehensive Cancer Network guideline panel membersAngela K Green, Brooke Barrow, Peter B Bach
JAMA|August 26, 2016
Time to Reassess the Cancer Compendia for Off-label Drug Coverage in OncologyAngela K Green, William A Wood, Ethan M Basch
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2019
Review of Current Policy Strategies to Reduce US Cancer Drug CostsAngela K Green, Jennifer A Ohn, Peter B Bach
JAMA|March 9, 2026
Obesity and Cancer: A Translational Science ReviewSherry Shen, Kristy A Brown, Angela K Green, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
JAMA Network Open|January 19, 2021
Challenges in Assessing the Cost-effectiveness of Cancer ImmunotherapyAngela K Green
Gynecologic Oncology|July 27, 2021
Novel therapy in endometrial cancer: How much will we pay?Angela K Green, Vicky Makker
Annals of Internal Medicine|January 4, 2018
Model-Based Eligibility for Lung Cancer Screening: Where Theory Meets PracticeAngela K Green, Peter Bach
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2018
Can We Afford That CAR? Confronting the Effect of Novel Immunotherapies on Future Health Care CostsAngela K Green, Leonard B Saltz
Cancer|December 10, 2015
Genomic profiling of advanced bladder cancer to guide the use of targeted therapeuticsAngela K Green, Matthew I Milowsky
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|March 28, 2020
A Review of Immune Checkpoint Blockade Therapy in Endometrial CancerAngela K Green, Jacqueline Feinberg, Vicky Makker
The Lancet. Oncology|February 13, 2019
Female representation among US National Comprehensive Cancer Network guideline panel membersAngela K Green, Brooke Barrow, Peter B Bach
JAMA|August 26, 2016
Time to Reassess the Cancer Compendia for Off-label Drug Coverage in OncologyAngela K Green, William A Wood, Ethan M Basch
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2019
Review of Current Policy Strategies to Reduce US Cancer Drug CostsAngela K Green, Jennifer A Ohn, Peter B Bach
JAMA|March 9, 2026
Obesity and Cancer: A Translational Science ReviewSherry Shen, Kristy A Brown, Angela K Green, et al.
Pageof 4